According to the Consensus Estimates for Johnson & Johnson's fourth quarter and full-year profits, fourth-quarter revenues and earnings are expected to reach $22.54 billion and $2.01 each share, respectively.
JNJ Quarterly Revenue Projection
The healthcare bellwether has been performing admirably, with an average four-quarter profit surprise of 4.15%. It has exceeded expectations for earnings in all four quarters and delivered a profit surprise of 9.01% in the most recent reported period.
Due to significant growth in the market and share advancements, it is anticipated that stronger sales of important drugs, including Darzalex, Tremfya, and Erleada, will have propelled revenues in J&J's Innovative Medicines business.
Revenues for Darzalex could come at $3.06 billion, compared to the consensus record of $3.04 billion.
It's conceivable that other goods like Opsumit, Uptravi, and Invega Sustenna have seen growth. Top-line growth is probably a result of the quick uptake of new medications like Spravato, Tecvayli, Talvey, and Carvykti.
Management Anticipation On JNJ
A number of Stelara biosimilars are anticipated to be introduced in the US in 2025. In January 2025, Amgen AMGN introduced Wezlana, the first Stelara biosimilar. However, it is unlikely that Amgen's introduction of biosimilars impacted Stelara's revenues in the final quarter of 2024.
J&J's diverse business strategy is its greatest asset. After completely splitting off its consumer health division last year to form the recently listed firm Kenvue KVUE, J&J has become a two-sector business focused on the pharmaceutical and medical technology industries.
The Innovative Medicines section of J&J is expanding. The company has a promising R&D pipeline that can produce novel products and propel its development. It recently acquired Ambrx, Proteologix, and NM26 bispecific antibodies in Innovative Medicine and Shockwave and V-Wave in MedTech, which expanded its pipeline.
JNJ Key Growth Factor
J&J declared in January that it had reached a final deal to purchase Intra-Cellular Therapies ITCI for $132.00 each share, or roughly $14.6 billion. Through the acquisition, J&J's neuroscience pipeline will include Caplyta, the only licensed medication by Intra-Cellular Therapies for the therapy of schizophrenia and bipolar I and II depression.
Through the acquisition, JNJ will also have access to Intra-cellular Therapeutics' other CNS prospects, such as ITI-1284, which is under development for people with generalized anxiety disorder and psychosis and agitation associated with Alzheimer's disease.
JNJ Stock Forecast Technical Analysis
In the daily chart of JNJ stock price, the most recent selling pressure from the top found a bottom as it showed a bullish V-shape recovery from a valid liquidity zone. Primarily, the liquidity sweep from the 143.77 level with an immediate recovery suggests a bullish continuation but a confirmation is pending from the price action.
In the major daily structure, the 50 day Exponential Moving Average is the immediate resistance to look at. Overcoming this line could increase the buying possibility towards the 154.82 level.
In the confluence bullish signal, the volume structure looks optimistic as the highest activity level since April 2024 is spotted below the recent bullish order block zone.
On the opposite side, the Death cross formation is in play, followed by a bearish lower low formation. In that case, a failure to hold the price above the 50 day EMA could signal a potential selling opportunity, aiming for the 140.00 level.
